Related Experiment Video
Updated: May 17, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
[Polyneuropathy associated with monoclonal gammopathy of undetermined significance]
Marie Moth Henriksen1, Eva Brøsted Kolmos, Niels Abildgaard
1Neurologisk Afdeling, Odense Universitetshospital. mhen0085@regionh.dk
Abstract:
The prevalence of polyneuropathy in patients with monoclonal gammopathy of undetermined significance (MGUS) has been reported to be 10-50%. The majority of patients have a chronic, slowly progressive, distal, symmetric and predominantly sensory polyneuropathy. A caused relationship between polyneuropathy and immunoglobulin (Ig)M MGUS is better established than the relationship between polyneuropathy and IgG/IgA MGUS because of the observed binding of IgM to myelin sheaths and widening of myelin lamellae. In randomized controlled trials plasma exchange, immunosuppressive, rituximab and intravenous Ig have been found to have a clinical meaningful effect.
Related Concept Videos
Multiple Sclerosis l: Introduction
Myasthenia Gravis ll: Pathophysiology
Diabetic Neuropathy
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Neural Regulation
Nephrotic Syndrome I : Introduction
